Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer

Authors of this review breakdown real-world, multidisciplinary clinical practices and institutional protocols used for patient selection/screening, monitoring, and management of pneumonitis/interstitial lung disease associated with the use of trastuzumab deruxtecan in the treatment of metastatic HER2-positive breast cancer.